Ferring Pharmaceuticals 的膀胱癌药物Adstiladrin®nadofaragene firadenovec-vncg)日前收到了美国食品和药物管理局(FDA)的批准,将于2023下半年在美国上市。Adstiladrin®是一种基于腺病毒载体的新型基因疗法,用于治疗患有高危的卡介苗(B...
Adstiladrin, an intravesical therapy administered every three months, targets the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer. The FDA approval was based on results of the Phase 3 clinical trial, which met its ...
FDA approval history Drug class: miscellaneous antineoplastics En español Professional resources Adstiladrin prescribing information Nadofaragene Firadenovec-vncg (AHFS Monograph) Related treatment guides Bladder Cancer Further information Always consult your healthcare provider to ensure the information dis...
Side effects Dosage information During pregnancy FDA approval history Drug class: miscellaneous antineoplastics En español Patient resources Adstiladrin drug information Professional resources Nadofaragene Firadenovec-vncg monograph Related treatment guides Bladder Cancer Medical...
US FDA approval of Adstiladrin on December 16, 2022 was based on results of the Phase 3 clinical trial, which met its primary endpoint with more than half (51%, n=50 of 98; 95% CI 41 to 61) of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 disea...
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345. ...
Ferring Pharmaceuticals 的膀胱癌药物Adstiladrin®nadofaragene firadenovec-vncg)日前收到了美国食品和药物管理局(FDA)的批准,将于2023下半年在美国上市。Adstiladrin®是一种基于腺病毒载体的新型基因疗法,用于治疗患有高危的卡介苗(BCG, Bacillus Calmette-Guérin)-无反应的非肌层浸润性膀胱癌(NMIBC,non-mus...